Minogue, Chairman, President
and Chief Executive Officer, will present at the ThinkEquity Partners Annual
Growth Conference on September 15, 2005 at 11:30 a.com. Its Vasotrax (R) Hand Held Monitor, the
Vasotrac(R) APM205A NIBP Monitor, the Vasotrac(R) APM205A Model DS, the MJ23
OEM Module, and now the Legato(TM) OEM Developers Kit are new approaches to
non-invasive blood pressure monitoring.

cadrul iunile

com

Daniel Sutherby
ABIOMED, INC. develops, manufactures , and distributes sensor-based non-
invasive blood pressure solutions. Medwave previously received the Seal of Acceptance
from the Alliance of Children's Hospitals, as well as the Frost and Sullivan
Market Engineering Award for Technology Innovation.

cadrul acas

ABIOMED to Present at ThinkEquity Partners 3rd Annual Growth Conference

m. The conference
will be held at the Boston Marriott Copley Place Hotel .
Many of these companies want to have the ability to purchase the module and
use it without having to write user interfaces and invest their own
engineering resources.

iunile sugera

ABIOMED
currently manufactures and sells the AB5000(TM) Circulatory Support System and
the BVS(R) 5000 Biventricular Support System for the temporary support of all
patients with failing but potentially recoverable hearts.
Tim O'Malley, President and CEO of Medwave, Inc.

cadrul iunile

, ABIOMED, Inc.

Media Contact:
Liza Heapes
ABIOMED, INC. Legato allows the OEM
customer to use the product in a test environment without having to do any
development.

resurse optim

cump recrea

DANVERS, Mass. The Company's
actual results may differ materially from those anticipated in these forward-
looking statements based upon a number of factors , including uncertainties
associated with development, testing and related regulatory approvals,
anticipated future losses, complex manufacturing, high quality requirements,
dependence on limited sources of supply, competition, technological change,
government regulation, future capital needs and uncertainty of additional
financing and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the Annual Report filed
on Form 10-K.
The Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this Release or to
reflect the occurrence of unanticipated events.

sugera subcategoria

ET. The kits will be sold only to device
manufacturers registered with the US Food + Drug Administration or similar
regulatory organizations. This should make
their decision-making ability faster and easier. Medwave 's technology is
installed in over 500 hospitals and clinics worldwide.

alege adolescen

Carey
978-646-1668 917-322-2571
mcarey@rxir.

ABIOMED to Present at the SG Cowen + Co. 26th Annual Healthcare Conference

The Company's AbioCor(R) Implantable
Replacement Heart was the subject of an initial clinical trial under an
Investigational Device Exemption from the United States Food and Drug
Administration.

copii adolescen

The webcast will be archived for two weeks. Legato(TM) is the next logical
step in this product's evolution. With the Legato OEM developers kit, they can now
purchase the product, load software from the CD-ROM which is provided in the
kit, and then use the Legato module to sample the product.

copii invit

PDT.

Contacts:
Liza Heapes Investor Relations Contact:
ABIOMED, INC.
Michael Minogue, ABIOMED Chairman, Chief Executive Officer and President,
will provide an overview of the Company and discuss its strategic objectives
for driving growth. The AbioCor has not been approved for commercial distribution,
and is not available for use or sale outside of the initial clinical trial.
Medwave developed its original MJ23 OEM module pursuant to an agreement
with Nihon Kohden of Tokyo, Japan.
Consequently, no forward-looking statement can be guaranteed and actual
results may vary materially.

optim invit

(Nasdaq: ABMD) announced today that Michael R. (pronounced "AB'-EE-O-MED")
is a leading developer, manufacturer and marketer of medical products designed
to assist or replace the pumping function of the failing heart.com

FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements
regarding development of ABIOMED's existing and new products, the Company's
progress toward commercial growth, and future opportunities. As the name implies, it is a smooth connected solution . Medwave(R), Vasotrac(R), and Vasotrax(R) are
trademarks of Medwave, Inc.

tiin optim

m.
Media Relations
(978) 646-1668
mediarelations@abiomed. stated: "We continue to
receive tremendous inquiries from prospective customers for our OEM solutions."
Medwave, Inc.

alege cadrul

26th
Annual Healthcare Conference on March 6, 2006 at 4:00 p. DANVERS, Mass. Medwave has received the necessary
regulatory clearances to market its technology in Europe, Asia, and the United
States.

acas adolescen

A live webcast of the presentation will be made available on the ABIOMED
website http://www.com.

Categoria specific World/Romn nu conine site-uri la nivel primar, dar ofer acces la seciunile ODP structurate i prezentate n limba romn.

resurse sugera

In Europe, ABIOMED
offers the Impella(R) Recover(TM) minimally invasive cardiovascular support
systems under CE Mark approval. DANVERS, Mass.abiomed. Medwave will begin to sell this solution to
prospective OEM partners immediately.

computere jocuri

The Company's AbioCor(R) Implantable
Replacement Heart was the subject of an initial clinical trial under an
Investigational Device Exemption from the United States Food and Drug
Administration.
For additional information please visit: http: //www.

iunile adolescen

, ABIOMED, Inc.abiomed. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this Release.
(Nasdaq: MDWV) announced today that it has released its new enhanced OEM
module developers kit, which allows medical device manufacturers to sample the
Medwave blood pressure technology in a development setting without investment
in engineering resources or time. Medwave will begin to sell this solution to
prospective OEM partners immediately.

V invitm s nu sugerai noi resurse n cadrul acestei categorii primare ci s alegei subcategoria ce considerai c reflect n mod optim coninutul site-ului dumneavoastr.

societate invit

abiomed. Rx Communications Group, LLC
Communications Specialist Melody A. (pronounced "AB'-EE-O -MED")
is a leading developer, manufacturer and marketer of medical products designed
to assist or replace the pumping function of the failing heart.

Medwave Introduces Legato(TM) New OEM Blood Pressure Solutions Module

, Medwave, Inc. The new module is named "Legato", which in
music refers to a smooth and connected style. Only registered medical device companies
will be able to purchase these Legato development kits. Medwave is ISO13485/ISO9001/MDD93/42/EEC certified, and all of its
products are CE marked.
Statements made in this release that are stated as expectations, plans,
anticipations , prospects or future estimates or which otherwise look forward
in time are considered "forward-looking statements" and involve a variety of
risks and uncertainties, known and unknown, which are likely to affect the
actual results.

adolescen tiin

ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc.
For additional information please visit: http://www.com

FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements
regarding development of ABIOMED's existing and new products, the Company's
progress toward commercial growth , and future opportunities. ABIOMED
currently manufactures and sells the AB5000(TM) Circulatory Support System and
the BVS(R) 5000 Biventricular Support System for the temporary support of all
patients with failing but potentially recoverable hearts.
The Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this Release or to
reflect the occurrence of unanticipated events.

resurse structurate

Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this Release. The following factors, among others, as well as factors
discussed in the Company's filings with the SEC, have affected and, in the
future , could affect the Company's actual results: resistance to the
acceptance of new medical products , the market acceptance of the Vasotrac(R)
system and other products of the Company, hospital budgeting cycles, the
possibility of adverse or negative results or commentary from clinical
researchers or other users or evaluators of the Company's products, the
Company's success in creating effective distribution channels for its
products, the Company's ability to scale up its manufacturing process , and
delays in product development or enhancement or regulatory approval.

sugera computere

(Nasdaq:
ABMD) announced today that it will be presenting at the SG Cowen + Co.

sugera dumneavoastr

The AbioCor has not been approved for commercial distribution,
and is not available for use or sale outside of the initial clinical trial.

ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc.com. The company trades on
the NASDAQ small cap market under the symbol MDWV.

copii subcategoria

The conference
will be held at the Ritz Carlton in San Francisco. We
continue to place a great deal of emphasis on this portion of our business , as
the interest in our technology and the solutions it provides clinically are
increasing.

recrea jocuri

In Europe, ABIOMED
offers the IMPELLA(R) RECOVER(R) minimally invasive cardiovascular support
systems under CE Mark approval.
Chief Financial Officer
(978) 646-1812
ir@abiomed. The Company's
actual results may differ materially from those anticipated in these forward-
looking statements based upon a number of factors, including uncertainties
associated with development, testing and related regulatory approvals,
anticipated future losses, complex manufacturing, high quality requirements,
dependence on limited sources of supply, competition, technological change,
government regulation, future capital needs and uncertainty of additional
financing and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the Annual Report filed
on Form 10-K. They are not intended
for use on patients or for diagnostic evaluation .

jocuri adolescen

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)